Kura Oncology, Inc.
KURAHeld by 11 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying11 funds opened new positions. Short interest: 15.2% of float.
Held by 11 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying11 funds opened new positions. Short interest: 15.2% of float.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.